Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human open-label study of SAR443579 in relapsed or refractory CD123-positive hematologic malignancies
NL-OMON55908Phase 2Recruiting
- Sponsor
- Sanofi
- Start
- Jul 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of SAR443579 in acute myeloid leukemia (AML), B cell acute lymphoblastic leukemia (B-ALL), myelodysplastic syndrome (MDS) and 1 more (4 arms), sponsored by Sanofi. Primary endpoints: Maximum tolerated dose or maximum administered dose and Antileukemic activity at confirmed RP2D. Started Jul 2022; status: recruiting.
02
Drugs
SAR443579
03
Conditions
acute myeloid leukemia (AML)B cell acute lymphoblastic leukemia (B-ALL)myelodysplastic syndrome (MDS)Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Beyond the preview
Go deeper on NL-OMON55908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55908.